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This randomized study evaluated the efficacy and tolerability of continued treatment with protease
inhibitor plus nucleoside-analogue combination regimens (n ¼ 79) or a change to the simplified
regimen of abacavir-lamivudine-zidovudine (n ¼ 84) in patients with suppressed human immuno-
deficiency virus type 1 (HIV-1) RNA for >6 months who did not have the reverse transcriptase 215
mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and
15% in the simplified group (P ¼ .081). Previous zidovudine monotherapy or dual therapy and
archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant
predictors of failure. Study treatment was discontinued because of adverse events in 20% of the con-
tinuation and 7% of the simplified group (P ¼ .021). Simplification to abacavir-lamivudine-zido-
vudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch
strategy carries a risk of virologic failure when treatment history or resistance testing suggest the
presence of archived resistance mutations to the simplified regimen.
High pill burden, food and fluid requirements, and side ef-
fects are major constraints for human immunodeficiency virus
(HIV)–infected patients undergoing protease inhibitor (PI)–
containing combination therapy. Although treatment simplifica-
tion could help patients to maintain adherence—an important
determinant of treatment success [1, 2]—continued virologic
suppression must be ensured. Induction and maintenance stra-
tegies have been studied previously to determine their effective-
ness in maintaining virologic suppression. After triple induction
treatment for 3–6 months, 22%–31% of patients with virologi-
cal suppression who reduced their therapy to lamivudine-zido-
vudine, lamivudine-indinavir, or indinavir alone experienced
rapid virologic rebound [3, 4]. Similarly, reduction to 2 drugs
after quadruple induction treatment failed to maintain virus sup-
pression [5]. Zidovudine resistance at baseline, poor adherence,
and low plasma levels of indinavir during maintenance therapy
predicted virologic failure [3, 6, 7]. Thus, an optimal mainte-
nance regimen must be potent but also easy to take.
We recruited patients being treated with PI-containing com-
bination regimens who experienced virological suppression for
>6 months. On the basis of the assumption of similar antiviral
potency, patients were randomized either to continue their current
therapy or to change to abacavir-lamivudine-zidovudine. The
main objective of the study was to determine the treatment effi-
cacy of this regimen, which is simplified in terms of fewer pills
and simpler dosing requirements. Additionally, we hypothesized
that a switch from PI-containing therapy to 3 nucleoside-ana-
logue reverse-transcriptase inhibitors (NRTIs) may have a ben-
eficial effect on lipid abnormalities associated with PIs [8–10].
Patients and Methods
Study participants. We recruited from our outpatient clinics
HIV-1–infected patients >18 years old whose plasma virus levels
had been ,400 HIV-1 RNA copies/mL (Roche Amplicor HIV-1
Monitor assay, version 1.0) for >6 months as a result of stable PI
and NRTI combination therapy. None of the patients had ever re-
ceived nonnucleoside reverse-transcriptase inhibitors (NNRTIs),
either by prescription (this drug class was not available before the
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recruitment time) or in a trial. At screening, the plasma HIV-1 RNA
level had to be,50 copies/mL (Roche Amplicor HIV-1 Ultrasensi-
tive Monitor assay, version 1.5). Exclusion criteria were previous
administration of abacavir, known previous failure of treatment
with lamivudine and zidovudine given simultaneously, and abnor-
malities in hematology (hemoglobin level ,10 g/dL for men or ,9
g/dL for women, neutrophil count ,1000 cells/mm3, or platelet
count,75,000 cells/mm3) or blood chemistry (alanine aminotrans-
ferase level .5 times the upper limit of normal or amylase level
.1.5 times the upper limit of normal). On the basis of preliminary
results of the AIDS Clinical Trials Group protocol 343 [3], patients
were also excluded if an archived reverse transcriptase mutation at
codon 215 was detected in their proviral DNA at screening or in the
plasma RNA–derived sequence from the most recently stored sample
with an HIV-1 RNA level of >1000 copies/mL for those without
recoverable proviral DNA. Amplification and sequencing were done
as described elsewhere [11, 12]. Proviral DNA was subjected to nest-
ed polymerase chain reaction, to analyze codons 130–228 of the
reverse transcriptase gene; only mutations at codons 184, 215, and
219 were reported. Patients without amplifiable proviral DNA and
without stored frozen plasma were allowed to enter the trial.
Study design. This was a prospective, randomized, controlled,
open-label study conducted in 8 HIV outpatient clinics in Switzer-
land and Milan, Italy. Randomization was done by central fax, with
use of a computerized schedule with randomly permutated block
sizes of 2 and 4, stratified by center and by prior duration of unde-
tectable plasma HIV-1 RNA (<9 or .9 months). Patients either
continued their current regimen (continuation group) or switched
to abacavir (300 mg) plus a lamivudine-zidovudine (150/300 mg)
combination tablet (Combivir), each twice daily (simplified group).
In February 2000, the simplified regimen was modified to consist
of only 1 triple-combination tablet twice daily (Trizivir; abacavir-
lamivudine-zidovudine [300/150/300 mg]). Change in therapy was
not permitted, except in case of treatment-limiting toxicity and only
after approval by the study headquarters. These patients remained
in the study, as did those who received a new regimen because of
virologic failure.
Assessments and study end points. Study visits were every 4
weeks until week 48 and every 6 weeks thereafter until the last re-
cruited patient completed 48 weeks of follow-up. Waist and hip cir-
cumference were measured every 12 weeks. Plasma HIV-1 RNA was
measured every 4 weeks until week 24 and every 12 weeks there-
after. CD4þ and CD8þ T cell numbers were determined every 12
weeks by use of a whole blood preparation method (Coulter) and
3-color flow cytometry [13]. In all Swiss centers, coexpression of
CD38 and HLA-DR activation markers on CD8þ T cells was also
measured. Optional tonsil biopsies were done for 23 patients from
2 centers after 1 year of randomized treatment. Virus loads in tonsil
biopsy samples and in peripheral blood mononuclear cells (PBMC)
of these patients were measured as reported elsewhere [14–16]. For
patients with virologic failure, frozen PBMC from day 0 and plasma
from the time of failure (first and confirmatory blood draw) were
retrospectively retrieved, and the full sequence of the reverse tran-
scriptase gene was analyzed. In patients with failure of continuation
therapy, the protease gene was also sequenced.
The primary end point of the study was the number of patients
with virologic failure, defined as a plasma HIV-1 RNA level of
.400 copies/mL in 2 consecutive samples. Additional end points
were treatment failure (defined as virologic failure, any change of
randomized therapy, or loss to follow-up), tolerability, metabolic
parameters, including nonfasting blood lipid measurements, and
the development of resistance.
Statistical analysis. On the basis of results of previous trials [3,
4], the study was powered to detect a higher rate of virologic failure
in the simplified group. Assuming a 5% significance level and power
of 80%, 156 patients (78 per arm) were required to detect a failure
rate of 10% and 25% in the continuation and simplified groups, re-
spectively. The protocol included an interim analysis after the first 40
participants in the simplified group reached week 16. The study would
have been discontinued if the virologic failure rate had been>25%.
The primary comparison was done on the intent-to-treat popu-
lation fulfilling all of the inclusion criteria and having taken at least
1 dose of randomized treatment. Results of changes from baseline
in laboratory values are expressed as medians with interquartile
ranges. To compare groups, Fisher’s exact test (for categorical vari-
ables) or the Mann-Whitney U test was used (GraphPad Prism, ver-
sion 3.00 for Windows; GraphPad). Stata software (version 7.0;
StataCorp) was used for Cox proportional hazards regression analy-
sis. The final model of the multivariable Cox regression analysis
was chosen by a stepwise backward selection procedure.
Results
Patients. Patients were recruited between January 1998 and
May 1999, with last follow-up in October 2000. Overall, 172 pa-
tients were randomized (figure 1). After exclusion of 3 patients
who did not come for the day 0 visit and 6 with a protocol viola-
tion (1 patient with virus suppression of ,6 months and 5 pa-
tients for whom the finding of a plasma RNA mutation at codon
215 was received only after their randomization), 79 patients
in the continuation and 84 in the simplified group were evalu-
able for the primary trial comparison. Baseline characteristics
were comparable, although slightly more patients in the continu-
ation group had previously taken zidovudine monotherapy or dual
therapy (48% vs. 37%; P ¼ :16; table 1). At the time of ran-
domization, antiretroviral therapy included stavudine for 46%
of patients in the continuation group versus 39% of patients in
the simplified group and zidovudine for 54% in the continuation
versus 61% in the simplified group. None of the patients had
received abacavir before beginning the study. The PI taken by
patients in the continuation group was indinavir for 52%, nel-
finavir for 20%, ritonavir for 14%, saquinavir for 3%, and saqui-
navir plus ritonavir for 11%.
Results of genotypic resistance testing at screening were avail-
able for 150 (92%) of 163 patients, 131 from HIV-1 DNA from
PBMC and 19 from HIV-1 RNA from previously stored plasma.
For 2 patients, nucleic acid was not amplifiable from either PBMC
or plasma, and, for 11 patients without amplifiable HIV-1 DNA
from PBMC, no frozen plasma from a previous time with detect-
able viremia was available (figure 1). Resistance mutations at
codon 184 or 219 were slightly more frequent at baseline in the
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continuation group (13 [19%] of 70 vs. 8 [10%] of 80; P ¼ :16;
table 1).
Median study duration was 84 weeks, totaling 268 patient-
years of observation. Twelve patients (15.2%) in the continu-
ation and 6 (7.1%) in the simplified group discontinued the study
prematurely or were lost to follow-up (table 2).
Virologic and treatment failure. In the intent-to-treat analy-
sis of the overall population, virologic failure was more frequent
in the simplified than in the continuation group, with 13 patients
(15%) versus 5 patients (6.0%) experiencing treatment failure
(P ¼ :081, Fisher’s exact test; table 2). Time to virologic failure
was also shorter in the simplified group (P ¼ :066, log rank test;
figure 2, middle). Virologic failure during randomized therapy
occurred more frequently in the simplified than in the continu-
ation group: 12 (14%) versus 2 patients (2.5%; P ¼ :01, Fisher’s
exact test).
Time to treatment failure was similar between groups (P ¼ :46,
log rank test; figure 2, top). In the intent-to-treat analysis, 25 pa-
tients (32%) in the continuation group, compared with 22 (26%)
in the simplified group, experienced treatment failure (table 2).
Adverse events were more frequently the reason for treatment
failure in the continuation group (16 vs. 6 patients; P ¼ :021).
Reasons for treatment change because of adverse events in the
continuation versus the simplified group were gastrointestinal
intolerance (6 vs. 1), new occurrence or worsening of lipodystro-
phy (6 vs. 0), hyperlipidemia (1 vs. 0), nephrolithiasis (1 vs. 0),
abacavir hypersensitivity (0 vs. 1), anemia or leukopenia (0 vs.
2), and other (2 vs. 2).
Characterization of virologic failures. Most of the virologic
failures in the simplified group (8 [62%] of 13) occurred before
week 20, whereas failures in the continuation group occurred be-
tween week 21 and 49 (table 3). At the time of virologic failure,
the physician’s opinion for the reason for virologic failure was
poor adherence in 5 of 13 patients in the simplified and in 1 of 5
Figure 1. Profile of randomized trial of simplified maintenance
therapy with abacavir, lamivudine, and zidovudine in human immunode-
ficiency virus–infected patients. PBMC, peripheral blood mononuclear
cells.
Table 1. Demographic data at time of randomization of human im-
munodeficiency virus (HIV)–infected patients to continuation therapy
with protease inhibitor plus nucleoside-analogue combination regi-
men or simplified regimen of abacavir-lamivudine-zidovudine.
Factor
Continuation
group (n ¼ 79)
Simplified
group (n ¼ 84)
Male 60 (76) 66 (79)
HIV risk factor
Homosexual activity 40 (51) 43 (51)
Heterosexual activity 18 (23) 18 (21)
Injection drug use 20 (25) 21 (25)
Blood products or undetermined 1 (1) 2 (2)
CDC disease stage
A 47 (59) 51 (61)
B 18 (23) 17 (20)
C 14 (18) 16 (19)
Age, median years (range) 41 (27–65) 38 (23–66)
Duration of suppressed HIV-1 RNA,
median months (range) 15 (6–30) 14 (7–27)
Duration of prior therapy,
median months (range)
Antiretroviral therapy 27 (11–106) 21 (10–82)
PI-containing antiretroviral therapy 20 (11–38) 18 (10–54)
NRTI before start of PI therapy
Any NRTI 40 (51) 35 (42)
Including zidovudine 38 (48) 31 (37)
Including lamivudine
(with prior zidovudine)
14 (18) 13 (15)
Genotypic resistance
Result available 70 (89) 80 (95)
Mutation at codon 184 10/70 (14.3) 6/80 (7.5)
Mutation at codon 219a 4/70 (5.7) 2/80 (2.5)
CD4þ lymphocyte count,
median cells/mm3 (IQR)
513 (377–645) 512 (348–778)
CD8þ lymphocyte count,
median cells/mm3 (IQR)
907 (673–1201) 854 (680–1067)
Cholesterol, median mg/dL (IQR)b 214 (181–251) 220 (195–255)
Triglycerides, median mg/dL (IQR)b 157 (113–279) 187 (134–283)
NOTE. Data are no. (%) of patients, unless specified otherwise. Baseline
parameters did not differ significantly between groups. IQR, interquartile range;
PI, protease inhibitor; NRTI, nucleoside-analogue reverse-transcriptase inhibitor.
a One patient in continuation group had both 184 and 219 codon mutations.
b Nonfasted values.
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patients in the continuation group, whereas the remaining cases
were deemed to represent insufficient treatment potency. Seven
of 13 patients who experienced virologic failure while taking
the simplified regimen received a new regimen including a PI.
Six, who also changed at least 1 NRTI, had subsequent plasma
HIV-1 RNA level of ,50–80 copies/mL during follow-up of
32–48 weeks (1 of the centers used the threshold of 80 copies/
mL for follow-up measurements). One patient, whose only change
was replacement of abacavir with nelfinavir, failed to respond.
Five patients chose to continue the simplified regimen and had
viremia always ,4000 HIV-1 RNA copies/mL during further
follow-up. One patient with treatment failure on day 0 experi-
enced full virologic suppression after switch to the simplified re-
gimen. Of the 5 patients in the continuation group with treatment
failure, 2 stopped all treatment and 3 chose salvage regimens, re-
sulting in HIV-1 RNA levels of ,50, 478, and 140,000 copies/
mL after a median treatment duration of 16 weeks.
Genotypic analyses of the patients with virologic failure are
summarized in table 3. In most patients with virologic failure,
a wide range of resistance-conferring reverse transcriptase mu-
tations was detected at the time of failure. However, several of
these mutations, particularly among the simplified group, were
already detected at baseline when proviral DNA from PBMC
was analyzed retrospectively. These data indicate that, after
switch to abacavir-lamivudine-zidovudine, reemergence of ar-
chived resistant virus may be a more important reason for viro-
logic failure than development of new resistance mutations
during simplified therapy.
History of previous mono- or dual zidovudine therapy was
noted in most patients with virologic failure and was a predictor
for virologic failure in the simplified group (9/31 patients with
vs. 4/53 without prior zidovudine; odds ratio, 5.01; 95% confi-
dence interval [CI], 1.39–18.0; P ¼ :013, Fisher’s exact test)
and in the entire patient population (13/69 with vs. 5/94 with-
out prior zidovudine; odds ratio, 4.13; 95% CI, 1.40–12.2; P ¼
:010). When patients were stratified by history of mono- or dual
zidovudine therapy, the risk of virologic failure among the 31
patients in the simplified group who had a history of zidovudine
treatment was 23.5% after 48 weeks and 33.3% after 96 weeks;
however, the risk of virologic failure was ,6% after 48 weeks
and ,11% after 96 weeks for those without prior zidovudine
mono- or dual therapy, independently of simplification (Kaplan-
Meier analysis; figure 2, bottom). In a multivariable Cox re-
gression analysis for all 150 patients with available results from
baseline resistance testing, previous zidovudine mono- or dual
therapy (hazard ratio, 3.78; 95% CI, 1.13–12.6; P ¼ :030), re-
sistance mutation in codon 184 or 219 of the reverse transcrip-
tase at baseline (hazard ratio, 4.23; 95% CI, 1.17–15.3; P ¼
:028), and higher CD8þ lymphocyte count at randomization (ha-
zard ratio, 1.14/100-cell increase; 95% CI, 1.001–1.29; P ¼ :048)
were predictive of subsequent virologic failure (table 4).
Lymphocyte subpopulations and virus load in cellular com-
partments. CD4þ T cells continued to increase throughout the
study, with little difference between the groups (figure 3). CD8þ
T cell numbers remained unchanged over time in both groups;
the median changes at week 48 from baseline were þ52 cells/
mm3 (interquartile range, 273 to þ205 cells/mm3) and þ58
cells/mm3 (interquartile range, 250 to þ122 cells/mm3) in the
continuation and simplified groups. In the subset of 130 patients
from the Swiss centers, CD8þ T cells were further examined for
Table 2. Virologic and treatment failure among human immunodeficiency virus (HIV)–infected pa-
tients randomized to continuation therapy with protease inhibitor plus nucleoside-analogue combination
regimen or simplified regimen of abacavir-lamivudine-zidovudine.
Parameter
Continuation group
(n ¼ 79)
Simplified group
(n ¼ 84) P
Duration of follow-up
Median weeks 83 85
Total patient-years 126 142
No. (%) with virologic failure, ITTa 5 (6) 13 (15) .081
History of Zdv mono- or dual therapy 4/38 (10.5) 9/31 (29.0)
No prior Zdv mono- or dual therapy 1/41 (2.4) 4/53 (7.5)
No. (%) with treatment failure, ITT 25 (32) 22 (26) .49
Premature end of randomized therapyb 23 9 .005
Changed >1 drug because of adverse event 16 6 .021
Discontinued/lost to follow-up 12 5 NA
Deathc 0 1 NA
Virologic failure during randomized therapy 2 12 .01
Virologic failure on day 0 (before switch) 0 1
NOTE. P values are derived from Fisher’s exact test. ITT, intent-to-treat, including those who switched treat-
ment; NA, not applicable; Zdv, zidovudine.
a Stratification based on history of Zdv mono– or dual–nucleoside analogue therapy.
b Subcategories of reasons for premature end of randomized therapy are not mutually exclusive (8 patients with-
drew subsequent to change in therapy).
c Non-Hodgkin’s lymphoma.
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CD38 and HLA-DR activation markers. CD8þ T cells were pre-
dominantly negative for both CD38 and HLA-DR activation
markers throughout the study in both groups. CD38þHLA-DRþ
CD8þ T cell numbers, assessed as a possible marker of persis-
tent low-level viral replication, remained low, with medians of
23 cells/mm3 at week 0 and at week 48 in the continuation group
and medians of 20 cells/mm3 at week 0 and 17 cells/mm3 at week
48 in the simplified group.
Nine patients in the continuation and 14 in the simplified
group, all of whom were receiving their randomized treatment
and had plasma HIV-1 RNA levels suppressed to ,50 copies/mL
between week 24 and 48, consented to have tonsil biopsies done
after 1 year of study treatment. At this time point, virus load in ton-
sils did not differ between groups: the mean (^SD) HIV-1 RNA
load was 0:667 ^ 0:655 log10 copies/mg of total RNA in the con-
tinuation group versus 0:538 ^ 0:572 log10 copies/mg of total
RNA in the simplified group, and the mean HIV-1 DNA load
was 2:511 ^ 0:547 log10 proviral copies/10
6 cells in the contin-
uation group versus 2:468 ^ 0:300 log10 proviral copies/10
6
cells in the simplified group. HIV-1 RNA and DNA were also
measured in PBMC from these patients at weeks 0, 48, and 96.
The mean values ranged from 0.89 to 1.37 log10 copies/mg of
total RNA for HIV-1 RNA and from 2.1 to 2.4 log10 proviral
copies/106 cells for HIV-1 DNA, with no significant difference
either between the groups or between the 3 time points.
Metabolic outcomes. In the simplified group, nonfasting
serum cholesterol levels decreased from baseline by a median of
35 mg/dL at week 4 and remained reduced thereafter (figure 4).
The changes from baseline differed between the 2 groups at all
time points (P , :002). Because high-density lipoprotein choles-
terol remained unchanged in both groups, the reduction in total
cholesterol in the simplified group was the effect of decreased
non–high-density lipoprotein fractions. There was also a signi-
ficant difference in the change from baseline in nonfasting tri-
glyceride levels, with a reduction by 43 mg/dL at week 48 in the
simplified group. Only 10 and 3 patients in the continuation and
simplified groups, respectively, received lipid-lowering drugs
during the study. Weight and waist-to-hip ratio did not change
throughout the study in either group (data not shown).
Clinical events. During the course of the study, 2 patients
in each group developed new HIV-associated illnesses: syno-
vial mycobacteriosis and oral thrush in the continuation group
and cryptosporidiosis and 1 death due to non-Hodgkin’s lym-
phoma in the simplified group.
Overall, 65 treatment-related adverse events occurred in 34
patients in the continuation group and 66 occurred in 38 patients
in the simplified group. However, discontinuation of random-
ized treatment due to adverse events was more frequent in the
continuation group (see above), mainly because of gastrointesti-
nal intolerance and lipodystrophy. Five serious treatment-related
adverse events were reported: 1 myocardial infarction, 1 nephro-
lithiasis attributed to indinavir, and 1 unilateral gynecomastia
(requiring surgical excision) in the continuation group and 1 aba-
cavir hypersensitivity with rash and fever and 1 neutropenia in
the simplified group. In addition, 1 myocardial infarction that
was not considered treatment-related occurred in the simplified
group.
Figure 2. Probability of treatment failure (top; P ¼ :46, log rank
test) and of virologic failure (middle; P ¼ :066, log rank test) in hu-
man immunodeficiency virus–infected patients receiving continuation
(cont; dashed line) or simplified (simp; solid line) therapy. “N co”
and “N si” are nos. of subjects in continuation and simplified groups,
respectively, at each time point. Bottom, Probability of virologic failure
after patients were stratified by history of previous zidovudine (Zdv)
mono- or dual therapy (solid lines, no prior Zdv mono- or dual-
nucleoside therapy; shaded lines, history of prior Zdv mono- or dual-
nucleoside therapy).
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Discussion
In this prospective, randomized trial, we tested the hypothesis
that HIV-1–infected patients who have been virologically sup-
pressed as a result of a PI- and NRTI-containing regimen may
simplify their therapy by switching to the triple-NRTI combi-
nation of abacavir-lamivudine-zidovudine. In the overall popu-
lation, virologic failure was more frequent (15% vs. 6%; P ¼
:081) and occurred faster in the simplified group (P ¼ :066, log
rank test). On the other hand, more patients in the continuation
group changed treatment because of adverse events (20% vs.
7%; P ¼ :021), leading to similar rates of overall treatment fail-
ure (32% vs. 26%; P ¼ :49).
The virologic failure rate in the simplified group was at least
partially driven by a high failure rate (9 [29%] of 31) among pa-
tients with a history of zidovudine mono- or dual therapy. Al-
though we performed genotypic resistance testing on HIV-1 DNA
from PBMC at baseline and—on the basis of preliminary results
of the ACTG 343 trial [3, 4]—excluded patients with the key zido-
vudine resistance mutation at codon 215, patients with other
mutations of the reverse transcriptase (e.g., codon 184 or 219)
were able to enter the trial. Resistance mutations at codon 184
or 219 and history of prior zidovudine mono- or dual therapy
were subsequently identified as significant predictors of viro-
logic failure by multivariable Cox regression analysis. Baseline
zidovudine resistance mutations have been previously reported
to predict loss of virus suppression during maintenance therapy
[3], and multiple zidovudine and lamivudine resistance muta-
tions cause cross-resistance to abacavir [17]. This stresses the
importance of carefully assessing previous treatment history in
potential candidates for treatment simplification, because the ge-
notypic assay may not detect mutations expressed at low level in
the archived virus. The latter concept is indirectly supported by the
high rate of virologic failure observed in patients with previous
exposure to zidovudine even in the absence of a resistance muta-
tion at baseline. Although the impact of treatment history with
other NRTIs could not be assessed in this study because zidovu-
dine was the agent predominantly administered in mono- or dual
therapy, our data indicate that archived virus resistant to NRTIs
can quickly become the dominant circulating virus population if
the new regimen is not fully suppressive.
Virologic failure was 3.8% after 48 weeks in patients who re-
placed the PI with abacavir and continued their prior NRTIs in
another trial; in that trial, only 9% of patients were NRTI-pre-
treated [18], compared with 46% in our population. Among the
Table 3. Resistance testing in patients with virologic failure (intent-to-treat analysis) in study of continuation therapy with pro-
tease inhibitor plus nucleoside-analogue combination regimen or simplified regimen of abacavir-lamivudine-zidovudine.
Group, study
week at which
failure occurred Adherencea
Prior zidovudine
without PI,
weeks
Mutations in RT (or RT
and Pr) DNA (PBMC)
at baselineb
Mutations in RT (or RT
and Pr) RNA (plasma)
at treatment failureb
Simplified
0 Poor 27 None 184V
5 Good 43 41L,184I 41L, 184V, 210W, 215Y
8 Good 17 None 41L, 184V, 215Y
8 Good 38 None 41L, 67N, 70R, 215F, 219
8 Good 165 67N,70R 67N, 70R, 184V, 215F, 219Q
16 Good 75 None 41L, 184V, 215Y
17 Good 0 67N,70R,184V 67N, 69D, 70R, 184V
19 Poor 0 None No amplification
36 Good 44 None 41L, 67N, 184V, 210W, 215Y
44 Poor 0 70K/R 67N, 69N, 70R, 184M/V, 215F, 219Q
69 Poor 178 67D/N,215T/F,219K/E 67N, 70R, 181Y/C, 184V, 215F, 219E
83 Good 0 None 184V
86 Poor 17 184V 41L, 184V, 215Y
Continuation
21 Poor 0 RT; no amplification None
Pr; ND at baseline 63C, 77I
23 Good 9 RT; 215T/F None
Pr; 63P 48V, 54V/I, 63P, 82A
26 Good 164 RT; 70K/R 41L, 67N, 70R, 184V, 215F, 219Q
Pr; 33V 30N, 33V
38 Good 96 RT; 70R 67N, 69S, 70R, 184V, 219Q
Pr; 20I,63S 20I, 30N, 33F, 63S, 77I, 88D
49 Good 105 RT; none 41L, 184V, 215Y, 219Q
Pr; ND at baseline 63P
NOTE. ND, not done; PBMC, peripheral blood mononuclear cells; PI, protease inhibitor.
a Physician’s opinion for reason for virologic failure at time of virologic failure.
b For simplified group, mutations sought were in reverse transcriptase (RT) DNA and RNA; for continuation group, mutations sought were in RT
and protease (Pr) DNA and RNA.
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53 patients without prior zidovudine mono- or dual therapy in our
study, the risk of virologic failure after changing to abacavir-lami-
vudine-zidovudine was 5.7% at 48 weeks and 8.7% at 96 weeks
(Kaplan-Meier analysis). Therefore, the applied switch strategy
seems to be virologically safe as long as prior treatment history
and/or resistance testing suggest absence of resistance to the drugs
administered in the new regimen. The adequate virologic poten-
cy of abacavir-lamivudine-zidovudine per se has been demon-
strated in a comparative, double-blind trial in treatment-naive
patients [19], a population likely to lack preexisting resistance
mutations. Those patients in our trial who experienced treatment
failure with abacavir-lamivudine-zidovudine had multiple resis-
tance mutations to NRTIs, but a salvage regimen was usually
successful because of preserved activity of other drug classes.
CD4þ and activated CD8þ T cells, the latter known to be an
independent marker of persistent viral replication and poor
prognosis [20–22], showed a similar time course in both groups.
Of note, even after a median of 2 years of prior antiretroviral
therapy, CD4þ T cell counts continued to increase in both
groups during the study, supporting the concept of long-term
immune recovery in patients with continuously suppressed
viral replication [23, 24].
Previous studies suggest that, despite suppression of HIV-1
RNA in plasma, treatment with 2 NRTIs alone or NRTIs plus
nevirapine is less potent than NRTIs plus PIs or efavirenz to
suppress virus load in lymphoid tissue [25–27]. Therefore, we
analyzed cell-associated virus load in tonsil biopsy samples after
1 year of study treatment and found no differences between pa-
tients receiving the triple-NRTI combination and those receiv-
ing PI-containing regimens. Cell-associated HIV-1 RNA in
PBMC, which correlates with virus load in lymph nodes [28],
was additionally determined for those patients who underwent
tonsil biopsies and was similar between the groups, suggesting
that the potency of this triple-NRTI regimen to suppress viral
replication in cellular compartments is in the range of previously
reported results from patients treated with PI-containing regi-
mens [15, 29–31].
PI therapy is associated with hypertriglyceridemia and hy-
percholesterolemia [8–10]. In this study, patients in the sim-
plified group experienced statistically significant reductions in
nonfasting serum cholesterol and triglyceride concentrations,
which may decrease the risk of long-term cardiovascular mor-
bidity. The use of nonfasting blood samples partially limits the
interpretation of the triglyceride levels; however, fasting and
nonfasting triglycerides recently have been shown to correlate
well in a group of 24 HIV-infected patients [32].
The number of treatment changes due to adverse events may
be potentially biased because of the open-label nature of this
study. Change of therapy, however, was permitted only in cases
of severe or strongly disturbing toxicity after approval by the
study headquarters. Moreover, abacavir was not available in Swit-
zerland and Italy during most of the study duration, and patients
from the continuation group were not allowed to receive the sim-
plified medication. Therefore, the relatively high rate of treat-
ment changes in the continuation group seems to primarily reflect
long-term toxicity of PI and NRTI combination regimens.
Table 4. Risk for loss of virus suppression (Cox regression analysis, stratified by center) among human im-
munodeficiency virus (HIV)–infected patients randomized to continuation therapy with protease inhibitor plus
nucleoside-analogue combination regimen or simplified regimen of abacavir-lamivudine-zidovudine.
Variable
Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Simplified vs. continuation arm 2.51 (0.89–7.09) .082 3.65 (1.15–11.6) .029
Prior Zdv therapy without PI 3.17 (1.05–9.56) .041 3.78 (1.13–12.6) .030
Genotypic resistancea 4.48 (1.35–14.9) .014 4.23 (1.17–15.3) .028
CD8þ cell count at randomizationb 1.13 (1.02–1.27) .018 1.14 (1.001–1.29) .048
NOTE. Univariable results are derived from all 163 patients, except for baseline genotypic resistance, which was avail-
able for 150 patients only. Multivariable results are derived from 150 patients. Probability of overall model: P ¼ :001. CI,
confidence interval; HR, hazard ratio; PI, protease inhibitor; Zdv, zidovudine.
a Codon 184 or 219 resistance mutation at randomization.
b Per 100-cells/mm3 increase.
Figure 3. Changes from baseline (D) in CD4þ lymphocyte num-
bers, intent-to-treat analysis, of patients randomized to continuation
therapy (dashed line) or simplified therapy (solid line). Symbols rep-
resent medians; bars represent interquartile ranges. “N co” and “N si”
are nos. of subjects in continuation and simplified groups, respectively,
at each time point. Changes from baseline did not differ significantly
between arms.
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A high degree of adherence, ideally exceeding 90%–95%,
has been shown to be required for optimal virus suppression [1].
On the basis of self-reported percentage of pills taken to pills
prescribed during the time between study visits, the simplified
group had a significantly lower frequency of study visits with
adherence ,90% to any drug than did the continuation group
(data not shown). Although such a measurement is subjective,
the low number of daily pills and the good tolerability of the
simplified regimen are important features of a long-term thera-
peutic strategy and may help to maintain antiviral efficacy. This
is confirmed by additional randomized studies examining the
switch from PIs to either abacavir or nevirapine, which have re-
ported easier adherence and improved quality of life for patients
who switched [18, 33].
This study is limited with regard to including only patients
with PI but without NNRTI experience. In the population stud-
ied, changing to a triple-NRTI combination may not be the only
simplification choice. Replacing PIs with nevirapine or efavi-
renz has been done with good virologic success [33–36]. However,
pretreatment with NRTIs alone may also predispose to frequent
virologic failure after switching from PIs to NNRTIs, demon-
strated by failure rates ranging from 19% to 50% in patients with
prior NRTI experience [37–39]. Thus far, effects on clinical lipo-
dystrophy have not been conclusive with any switch strategy;
if the abnormal fat distribution regresses at all, it may require
several years.
In conclusion, treatment simplification from a PI-containing
regimen in patients with good virus suppression resulted in better
adherence, fewer adverse events leading to drug discontinua-
tion, and a clinically meaningful reduction in blood lipids. How-
ever, the rate of virologic failure was increased among patients
who changed to abacavir-lamivudine-zidovudine if they had pre-
viously received zidovudine or had evidence of resistance muta-
tions. This strategy, therefore, is appropriate only for patients
with no prior zidovudine mono- or dual therapy and no sugges-
tion or evidence of resistance to NRTIs.
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